


## How Glycemic Management Impacts Readmissions

Readmission rates are a key indicator of hospital quality, and high readmission rates following certain diagnoses and procedures can lead to penalties from CMS under the Hospital Readmissions Reduction Program (HRRP).<sup>1</sup>

While a number of variables can impact readmission rates, controlling patient blood glucose is an important factor. Hypoglycemia and hyperglycemia have both been proven to correlate with increased readmission rates.<sup>2</sup>



Through improved insulin dosing and administration, Glytec's eGlycemic Management System (eGMS) can help **reduce readmission rates by improving glycemic control.**<sup>3</sup>

eGMS is a modularized glycemic management software that can integrate with a hospital's EMR and LIS. Glucomanager, the core module, provides personalized recommendations for IV and SubQ insulin dosing. A guided workflow, safety alerts and surveillance allow providers to focus on patient safety.

# How eGMS reduces readmissions

Our FDA-cleared algorithm **delivers personalized dosing recommendations** that help improve patient outcomes:



eGMS gets patients into target blood glucose range faster.<sup>4</sup>



eGMS enables tighter control of patient blood glucose, reducing the incidence of both hyperglycemia and hypoglycemia<sup>5</sup> as well as perioperative complications.<sup>6</sup>




eGMS guides transitions from IV insulin to subcutaneous insulin as patients are transferred into step-down units.

## Evidence of reduced readmission rates using eGMS



Researchers compared the use of eGMS to Standard Care in 3198 patients who were admitted to a 13-hospital health system in 2015.

### Risk-Adjusted Readmission Rates



All patients in the study were undergoing treatment for acute myocardial infarction (AMI), treatment for congestive heart failure (CHF) or coronary artery bypass grafting (CABG) procedures. These diagnoses and procedures are used by CMS to calculate readmissions penalties.

Results indicated that patients treated with Standard Care were more likely to be readmitted than patients treated with eGMS.<sup>3</sup>



Researchers concluded that **glycemic control using eGMS can effectively reduce the rate of readmission** for patients with cardiovascular disease who are in need of insulin management.<sup>3</sup>

## Beyond readmissions

Reducing readmissions is just one way Glytec's eGMS improves patient safety and reduces costs for hospitals. eGMS has also been proven to:



Reduce the incidence of hypoglycemia and hyperglycemia<sup>5</sup>



Reduce average length of stay<sup>7</sup>



Save clinicians time.<sup>7,8</sup>



In fact, eGMS helped one 610-bed regional medical center **save over \$7 million in the first year.**<sup>7</sup>

## Let us answer your questions.

Contact Glytec to schedule a demo or discuss next steps.

GET IN TOUCH

(864) 370-3297

[glytecsystems.com](http://glytecsystems.com)

[info@glytecsystems.com](mailto:info@glytecsystems.com)

## References

1. Centers for Medicare & Medicaid Services. Hospital Readmissions Reduction Program (HRRP). 24 August, 2020. <https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/Readmissions-Reduction-Program>
2. Financial Implications of Poor Glycemic Management & Improvement Strategies for Optimal Outcomes. IHI Annual National Forum on Quality Improvement in Health Care, Dec 2018.
3. Relationship Between Glycemic Control Using eGMS and Readmission Rates in Cardiovascular Patients Hospitalized with AMI, CHF or Undergoing CABG During the Implementation of a System Wide Glycemic Initiative. Annual Diabetes Technology Meeting, Nov 2016.
4. Comparative Effectiveness of a Computerized Algorithm Versus a Physician Instituted Protocol to Manage Insulin Infusions After Cardiac Surgery. HMO Research Network Conference, Apr 2014.
5. Comparison of Hyperglycemia Management Protocols in the ICU: Standard Protocol versus eGlycemic Management System. American Diabetes Association Scientific Sessions, Jun 2019.
6. Hospitalization Costs and Clinical Outcomes in CABG Patients Treated with Intensive Insulin Therapy. Journal of Diabetes and Its Complications, Apr 2017.
7. Safely Converting From Sliding Scale to Basal Bolus Insulin Across an Entire Medical Center via Implementation of the eGlycemic Management System. American Diabetes Association Scientific Sessions, June 2017.
8. New Interfaces for eGlycemic Management System Save Nursing Time and Improve Patient Outcomes: Time and Motion Nursing Study. American Association of Clinical Endocrinologists Scientific & Clinical Congress, May 2014.

---

The eGlycemic Management System® is a modularized solution for glycemic management across the care continuum that includes Glucommander™. Glucommander™ is a prescription-only software medical device for glycemic management intended to evaluate current as well as cumulative patient blood glucose values coupled with patient information including age, weight and height, and, based on the aggregate of these measurement parameters, whether one or many, recommend an IV dosage of insulin, glucose or saline or a subcutaneous basal and bolus insulin dosing recommendation to adjust and maintain the blood glucose level towards a configurable physician- determined target range. Glucommander™ is indicated for use in adult and pediatric (ages 2-17 years) patients. The measurements and calculations generated are intended to be used by qualified and trained medical personnel in evaluating patient conditions in conjunction with clinical history, symptoms, and other diagnostic measurements, as well as the medical professional's clinical judgement. No medical decision should be based solely on the recommended guidance provided by this software program.

Glucommander™ is only available for use in the United States.

This content is only intended for use in the United States.

Customer service: (888) 458-2683